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 ABSTRACT 
 
Problem: Cataract removal surgery is one of the most common operative procedures 
performed. While the overall rate of postoperative endophthalmitis is low, the high 
number of procedures translates that low percentage of occurrence into thousands of 
patients affected by serious complications that could result in loss of eyesight, 
permanently decreasing quality of life. Methods: Peer-reviewed articles were found 
that described decreased rates of postoperative endophthalmitis with the use of various 
perioperative and intraoperative antibiotic regimens. Results: Prophylactic use of 
antibiotics is widespread practice; however, there are no standardized guidelines for 
best practice. Recent studies show decreased rates of postoperative endophthalmitis 
with intracameral antibiotics, with cefuroxime and moxifloxacin being the two most 
commonly used. Conclusions:  Use of a prophylactic intracameral antibiotic decreases 
the rate of postoperative endophthalmitis in cataract surgery patients. Intracameral 
antibiotic prophylaxis should be implemented as a standard of care. Further studies 
regarding the efficacy of different intracameral antibiotics would contribute to 
defining best practice recommendations in preventing postoperative endophthalmitis 
in cataract surgery patients.  
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Vision is controlled by different parts of the eye, notably the cornea, iris, lens, 
and retina. The cornea is the “window” to the eye that first refracts light, the iris 
regulates how much light enters the eye through the pupil, the lens allows for near and 
far accommodation in addition to further refracting and focusing light, and the retina 
contains photoreceptors that transmit signals to the visual cortex of the brain via the 
optic nerve.1 Of the many diseases and conditions that can affect each part of the eye 
and reduce vision, cataracts are the leading cause of blindness worldwide.2 
A cataract is an opacity of the intraocular lens that may be either congenital or 
acquired. The intraocular lens is composed of water and crystalline proteins, 
surrounded by a thin capsule and suspended by the ciliary zonules in the posterior 
chamber of the eye behind the iris.1 Acquired cataracts may be related to one or more 
conditions which can include age, genetics, ultraviolet light exposure, uveitis, steroid 
use, or trauma. Over time, cataracts mature to become significant enough to lead to 
visual impairment or blindness if not treated. 
The definitive treatment for a cataract is cataract extraction, usually with 
intraocular lens implantation, and is a commonly performed surgical procedure with 
the goals of improvement in visual acuity and prevention of blindness. Recent 
advances in cataract surgery include utilization of femtosecond lasers, extracapsular 
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cataract extraction by phacoemulsification, and multifocal or astigmatism correcting 
intraocular lens (IOL) implantation. 
A postoperative infection in the eye, or postoperative endophthalmitis, is a 
serious potential complication of cataract surgery that may result in blindness or even 
loss of the eye. Postoperative endophthalmitis may be caused by a break in aseptic 
technique, contaminated supplies or instruments, prolonged surgical time, surgical 
complications, or postoperative contamination of the wound. The current standard of 
care for prevention of postoperative endophthalmitis involves a preoperative prep with 
topical iodine. The use of various perioperative antibiotic eye drop regimens is 
routine, but the publication of the 2007 European Society of Cataract and Refractive 
Surgery (ESCRS) trial3 results showed a clear benefit of intracameral antibiotic use 
with a 4.92-fold increase (95% confidence interval, 1.87-12.9), in incidence of 
postoperative endophthalmitis without use of intracameral cefuroxime. 
Several studies have been published since the ESCRS trial4-12 to both evaluate 
the safety of intracameral antibiotics and determine the most effective antibiotic and 
dose concentration. Currently, intracameral cefuroxime and moxifloxacin appear to be 
the most widely used prophylactic intracameral antibiotics and there are several 
studies evaluating each of their uses.3-11 However, there are few studies to be found 
that compare their uses directly and no consensus or uniform guidelines on best 
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1.2 METHODS 
 
The Weill Cornell Medical Library online was utilized to search the PubMed 
database to obtain articles from peer-reviewed journals. Search terms used included 
“intracameral antibiotics” and “intracameral cefuroxime” as well as “intracameral 
antibiotics” and “intracameral moxifloxacin”. Articles were excluded based on the 
following criteria: articles published over five years ago with the exception of those 
that contributed significantly to the topic or have been deemed landmark studies, lack 
of topic relevance including articles that do not involve clinical or laboratory 
evaluation of intracameral antibiotic safety and/or use, multiple articles that focused 
on the same topic with smaller or older studies being excluded, and unavailability of 




Overall, 133 articles were found in the PubMed search. Initial results for the 
search “intracameral antibiotics” and “intracameral cefuroxime” yielded 81 articles. 
Initial results for the search “intracameral antibiotics” and “intracameral 
moxifloxacin” yielded 41 articles. Initial results for the search “intracameral 
cefuroxime” and “intracameral moxifloxacin” yielded 11 articles. Several articles 
were not included because they were repetitive with smaller or older studies being 
excluded, independent, small-scale clinical trials designed to evaluate and confirm the 
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The articles found for analysis can be categorized by evaluation of the safety 
and efficacy of intracameral cefuroxime, the safety and efficacy of intracameral 
moxifloxacin, or the safety and efficacy of intracameral use of both cefuroxime and 
moxifloxacin. 
Articles that evaluate the safety and efficacy of intracameral cefuroxime use 
 The European Society of Cataract and Refractive Surgery (ESCRS)3 results 
clearly showed a statistically significant benefit to administering intracameral 
cefuroxime. The benefit was so great (4.92-fold increase, 95% confidence interval, 
1.87-12.9, in incidence of postoperative endophthalmitis without use of intracameral 
cefuroxime) that the study was adapted from the planned inclusion of 35,000 patients 
to less than 17,000 because the ESCRS data monitoring committee came to the 
conclusion that it would be unethical to continue withholding prophylactic 
intracameral cefuroxime treatment from future study participants in the levofloxacin 
or no antibiotic groups. With results that so strongly indicated the use of intracameral 
cefuroxime, this study provided a well-supported answer to the question of whether or 
not prophylactic intracameral antibiotic use is of benefit in preventing the occurrence 
of postoperative endophthalmitis in cataract surgery patients. 
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A 2010 randomized controlled study by Lam et al7 investigated the safety of 
the prophylactic use of three different cephalosporins in cataract surgery. Cefazolin, 
cefuroxime, ceftazidime or normal saline was injected intracamerally at the end of 
cataract surgery and safety outcomes were measured by central endothelial cell density 
and retinal center point thickness preoperatively and three months postoperatively. 
The authors found no statistical differences in central endothelial cell density and 
retinal center point thickness between eyes that received any of the cephalosporins or 
normal saline beyond the expected effects of a normal cataract surgery. 
A 2013 report details the institution of intracameral cefuroxime at an English 
hospital and the protocol put in place for patients with a history of penicillin allergy.10 
While this study is small and simple in design, it offers valuable information regarding 
use of cefuroxime in patients with a history of allergy to penicillin, a major drawback 
and source of hesitation for clinicians in administration of prophylactic intracameral 
cefuroxime. Fifty patients with a history of penicillin allergy that was not suggestive 
of anaphylaxis received intracameral cefuroxime with no adverse reactions. 
Articles that evaluate the safety and efficacy of intracameral moxifloxacin use 
An in vitro study by Kernt et al6 aimed to investigate the safety of intracameral 
moxifloxacin on human ocular cells. The authors note the limited amount of data on 
prophylactic intracameral antibiotic administration, and are particularly interested the 
safety of intracameral moxifloxacin on ocular cells. Effects of moxifloxacin, 10-750 
mcg/ml, were evaluated after 24 hours of exposure in the setting of induced stress and 
inflammation on human corneal endothelial, trabecular meshwork, and retinal pigment 
cells. Toxicity was assessed by cell survivability rate and cell viability was done by 
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microscopy count. Results revealed no toxicity on corneal endothelial, trabecular 
meshwork, or retinal pigment cells at moxifloxacin concentrations up to 150 mcg/ml 
and support the safe use of prophylactic intracameral moxifloxacin to prevent 
postoperative endophthalmitis. 
A prospective, randomized, controlled study by Lane et al8 aimed to evaluate 
the safety of prophylactic intracameral moxifloxacin use in cataract surgery to prevent 
postoperative endophthalmitis. Safety was evaluated preoperatively and 
postoperatively for 3 months and included evaluation of visual acuity, intraocular 
pressure, endothelial cell counts, corneal pachymetry (thickness), corneal clarity and 
edema, and anterior chamber cells and flare. Results showed no statistical difference 
in optical tomography between the test and control groups preoperatively or at 3 
months postoperatively. Results also revealed no statistical difference in any of the 
safety parameters at postoperative day 1, 2 to 4 weeks, or 3 months. There were no 
study-related adverse events in either group. Results support the safety of intracameral 
use of 250 mcg moxifloxacin for prophylaxis against postoperative endophthalmitis.  
A cohort study by Galvis et al4 compared the rates of postoperative 
endophthalmitis before and after instituting use of intracameral moxifloxacin. Notably, 
this study evaluated the outcomes of a single surgeon, minimizing variability in 
perioperative surgical preferences and surgical technique. While the total number of 
eyes in the study was 2332 (1056 without intracameral moxifloxacin and 1618 with 
intracameral moxifloxacin), the results were not statistically significant. There was 
only 1 case of endophthalmitis in the group that did not receive intracameral 
moxifloxacin, and no cases in the group that did receive intracameral moxifloxacin. 
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The authors of the study note that to achieve statistically significant results the study 
would need to include 21,000 eyes treated with intracameral moxifloxacin and plan to 
continue the study to confirm the assumed trend of decreased postoperative 
endophthalmitis with intracameral moxifloxacin injection. 
A retrospective cohort study by Matsuure et al9 aimed to report 
endophthalmitis rates after cataract surgery and the incidence of complications after 
intracameral moxifloxacin injection. Nineteen clinics in west Japan participated in a 
retrospective survey of the 4 years before and after use of intracameral moxifloxacin 
and the number of cases of endophthalmitis within 1 month after surgery. The authors 
found 8 incidences of endophthalmitis in 15,958 cases prior to moxifloxacin injection, 
and 3 incidences of endophthalmitis in 18,794 cases after the addition of moxifloxacin 
injection. 
Matsuure et al note widespread use of intracameral antibiotics in Europe after 
the 2007 ESCRS study, but highlight that while growing in practice it is not yet 
common outside of Europe. When intracameral moxifloxacin is considered, there are 
even fewer studies, especially clinically or on a large scale. While this study was 
conducted on a large scale, not only was it retrospective, but also drew on data from 
several centers with varying protocols for intracameral moxifloxacin injection. The 
moxifloxacin dose administered varied from 50 mcg/ml to 500 mcg/ml, and one center 
injected the moxifloxacin into the continuous irrigation bottle as opposed to a single 
injection at the end of surgery. While a good start, it would be recommended to 
develop a large-scale prospective study on the use of intracameral moxifloxacin with 
uniform protocol. 
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Articles that evaluate the safety and efficacy of intracameral cefuroxime and 
moxifloxacin use 
An in vitro study by Haruki et al5 aimed to investigate and compare the toxic 
effects of moxifloxacin, cefuroxime and levofloxacin on corneal endothelial cells to 
determine safe intracameral concentrations. Toxicity was measured based on cell 
damage, cell viability, and cytokine secretion. The authors found that toxicity from 
cefuroxime required high doses (500 mcg/ml) and occurred at 24 hours. Toxicity from 
moxifloxacin also required high doses (350 mcg/ml for trabecular meshwork and 
retinal pigment cells) and occurred at 6 hours. The toxicity findings for levofloxacin 
were similar to moxifloxacin, but the minimum inhibitory concentration (MIC) for 
levofloxacin is much higher than moxifloxacin. The authors conclude that, while toxic 
at high doses, moxifloxacin is a viable alternative to cefuroxime and recommended for 
prophylaxis at under 500 mcg/ml. 
Shorstein et al11 published the first large-scale study in the United States in 
2013 confirming decreased rates of endophthalmitis with the use of intracameral 
antibiotics. The primary intracameral antibiotic utilized was reconstituted cefuroxime 
in 84% of cases and moxifloxacin in 15% of cases. Over a 5-year period intracameral 
antibiotic use increased from 11% to 100% and the patients who received intracameral 
antibiotics had a 13-fold lower rate of postoperative endophthalmitis. However, in 
spite of overwhelming evidence in support of the use of prophylactic intracameral 
antibiotics, the study authors acknowledge that an ecological timescale study is better 
suited to provide supportive evidence, and that a randomized controlled trial would be 
better to establish causation. 
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1.5 CONCLUSION 
 
Currently there are multiple clinical studies that evaluate the safety and 
efficacy of the prophylactic use of either intracameral cefuroxime or intracameral 
moxifloxacin for preventing postoperative endophthalmitis, as well as laboratory 
studies that compare the safety and efficacy of both cefuroxime and moxifloxacin. 
However, there has yet to be a large-scale direct clinical comparison of the two 
antibiotics. In light of the literature reviewed, the next step in defining the best use of 
intracameral antibiotics would be to design a large-scale clinical study to directly 
compare the use of intracameral cefuroxime versus the use of intracameral 
moxifloxacin for evaluation of the lowest incidence of postoperative endophthalmitis. 
 





Problem: Cataracts are the leading cause of blindness worldwide, and cataract surgery 
is one of the most common operative procedures performed. The number of cataract 
surgeries continues to increase as populations across the globe age, eg, Americans and 
the baby boomer population. While the overall rate of postoperative endophthalmitis is 
low, the high number of procedures translates a low percentage of occurrences into 
thousands of patients affected by serious complications that could cost them their 
eyesight, permanently decreasing their quality of life. Purpose: The purpose of this 
study will be to evaluate the efficacy of intracameral cefuroxime versus intracameral 
moxifloxacin in preventing postoperative endophthalmitis in cataract surgery patients 
to help define the best use of prophylactic intracameral antibiotics. Research 
Questions: Is there a difference in the rate of postoperative endophthalmitis after 
cataract surgery when using antibiotic prophylaxis with intracameral cefuroxime 
versus intracameral moxifloxacin? Is the difference in postoperative endophthalmitis 
rates after cataract surgery with prophylactic intracameral cefuroxime versus 
intracameral moxifloxacin statistically significant? Methods: The subjects of this 
study will be adult patients undergoing clear corneal incision cataract surgery without 
any additional planned procedures. The patients will be enrolled from participating 
hospitals and surgery centers and be randomized into one of two groups. Outcomes: 
The outcome of this study will provide evidence for whether or not there is a benefit 
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provided by use of one intracameral antibiotic over the other. Benefit: This study will 
help define standards for best use of intracameral antibiotic use for prophylaxis against 
postoperative endophthalmitis in cataract surgery patients. It will potentially reduce 
the rates of postoperative endophthalmitis and thereby further minimize the number of 
patients who suffer from vision or globe loss after cataract surgery. 
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2.2 AIMS 
 
2.2.1 Project Overview 
This study will assess the clinical efficacy of intracameral cefuroxime versus 
the clinical efficacy of intracameral moxifloxacin in prevention of postoperative 
endophthalmitis in cataract surgery patients. Past studies have demonstrated the safety 
and efficacy of prophylactic use of both intracameral cefuroxime and intracameral 
moxifloxacin; however, there is no clear consensus on the superiority of one antibiotic 
over the other and there has yet to be a large-scale direct clinical comparison. 
2.2.2 Research Questions 
1. Is there a difference in the rate of postoperative endophthalmitis after cataract 
surgery when using antibiotic prophylaxis with intracameral cefuroxime versus 
intracameral moxifloxacin? 
2. Is the difference in postoperative endophthalmitis rates after cataract surgery with 
prophylactic intracameral cefuroxime versus intracameral moxifloxacin 
statistically significant? 
2.2.3 Specific Aims 
AIM 1:  Create a two-armed study to investigate the clinical efficacy of intracameral 
cefuroxime versus intracameral moxifloxacin in prevention of postoperative 
endophthalmitis in cataract surgery patients. 
AIM 2:  Calculate the rates of postoperative endophthalmitis in patients who received 
intracameral cefuroxime versus intracameral moxifloxacin. 
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AIM 3:  Determine a preliminary best use recommendation for prophylactic 
intracameral antibiotic administration in cataract surgery patients to prevent 
postoperative endophthalmitis. 
2.2.4 Hypothesis 
As a fourth generation fluoroquinolone, moxifloxacin will have better 
prophylactic coverage than the second-generation cephalosporin, cefuroxime, and 
have a lower rate of incidence of postoperative endophthalmitis in cataract surgery 
patients. 
Null hypothesis: Neither intracameral cefuroxime or intracameral moxifloxacin will 
result in a statistically significant lower rate of postoperative endophthalmitis after 
cataract surgery. 
Hypothesis: Intracameral moxifloxacin will have a statistically significant lower rate 
of postoperative endophthalmitis after cataract surgery than intracameral cefuroxime. 
 
2.3 BACKGROUND AND SIGNIFICANCE 
 
2.3.1 Background 
Cataracts may be caused by any number of factors, including age. As advances 
in medicine continue to increase longevity, a growing number of people will 
experience a decrease in vision due to cataract formation. Cataract surgery is already 
the most commonly performed procedure worldwide. Millions of people will have the 
procedure performed on one or both of their eyes. When there are millions of people 
who will have a procedure that means there are millions of people who are at risk to 
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experience a complication from the procedure. Specifically, the risk of consequence in 
this setting is the incidence of postoperative endophthalmitis in cataract surgery 
patients. Although the rates of postoperative endophthalmitis are reported to be as low 
as 0.06-0.25%,14 the high number of surgeries performed translate into thousands of 
people who may experience a decrease in visual acuity, total vision loss or even loss 
of the globe based on sheer numbers. 
Although prophylactic use of antibiotics is widely accepted, there are no 
uniform guidelines or best practice recommendations regarding use of specific 
antibiotics or routes of administration.11 Prophylactic antibiotic regimens are selected 
based on surgeon preference and may include one or more of the following: 
preoperative eye drops, perioperative eye drops, postoperative eye drops, 
intraoperative intracameral administration through the irrigation fluid, and 
subconjunctival injection or intracameral injection at the end of surgery. 
Initial studies that demonstrated the benefit of using prophylactic intracameral 
antibiotics administered intracameral cefuroxime.3 Subsequent studies have followed 
that confirm prophylactic administration of intracameral cefuroxime reduced rates of 
postoperative endophthalmitis.7,10,11 Intracameral cefuroxime is currently the 
unofficial prevailing choice for intracameral antibiotic prophylaxis. Recent studies 
have shown that intracameral moxifloxacin also significantly reduces the rates of 
postoperative endophthalmitis in cataract surgery patients4,8,9 and could be a better 
alternative to intracameral cefuroxime since it has broader spectrum coverage as a 
fourth generation fluoroquinolone as opposed to a second generation cephalosporin, its 
antimicrobial properties are concentration-dependent instead of time-dependent,4,8,14 it 
  15 
does not require reconstitution and dilution from a powder,12,14 and eliminates concern 
regarding beta-lactam hypersensitivity.10,11,14 
2.3.2 Project Significance 
The ability to see is crucial to a person’s independence and quality of life. It 
may be one of the most important factors that affect quality of life since there is no 
way to make up for its complete loss. A person who is mute may learn to 
communicate via sign language, a person who loses their hearing or is born deaf may 
benefit from a hearing aid or cochlear implant, and there are many modalities and 
options for those who are affected by loss of the use of a limb or loss of a limb. 
There are ways to enhance or correct a person’s level of vision by use of 
glasses, contacts or laser surgery. There are ways to preserve a person’s level of vision 
by use of eye drops, shunts or other surgical procedures to decrease intraocular 
pressure, or laser retinopexy to halt progression of retinal damage. However, there is 
no way to replace vision once it has been permanently lost. For the thousands of 
cataract surgery patients who may be affected by permanent decrease in vision or 
complete vision loss due to complications from postoperative endophthalmitis, 
determining best practice recommendations for use of prophylactic intracameral 
antibiotics is necessary in an effort to further reduce the rates of postoperative 
endophthalmitis and preserve vision and quality of life in as many people as possible. 
 
2.4 PRELIMINARY STUDIES 
 
Not Applicable 
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2.5 RESEARCH DESIGN AND METHODS 
 
2.5.1 Design 
This will be a two-armed, multi-center, randomized control study. Both groups 
will consist of patients undergoing first or second eye cataract extraction with 
intraocular lens implant surgery, without any planned additional procedures eg, same 
day sequential cataract removal, pterygium excision, limbal relaxing incisions or 
trabeculectomy. Patients who undergo unplanned procedures eg, sulcus lens 
implantation, posterior capsule tear, vitrectomy or corneal incision closure with suture 
will remain in the study. 
One group will receive 1 mg intracameral cefuroxime, and the other group will 
receive 250 mcg intracameral moxifloxacin at the end of their cataract surgery. The 
group that receives intracameral cefuroxime will act as a control group since 
intracameral cefuroxime was the antibiotic utilized in the ESCRS trial. Additionally, 
withholding intracameral antibiotic administration would be unethical since the use of 
intracameral antibiotics has been shown to significantly reduce the rates of 
postoperative endophthalmitis. 
2.5.2 Methods 
Study approval from the appropriate institutional review board (IRB) will be 
obtained prior to proceeding with recruitment of participants. All patients seen by 
participating attending and/or resident surgeons at selected institutions who meet 
selection criteria will be approached for participation. Participants will sign IRB-
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approved consent for enrollment in the study. Participants will be selected based on 
the following criteria: 
1. Must be diagnosed with a clinically significant atraumatic cataract. 
2. Must opt for elective surgery prior to approach for participation. 
3. Must be undergoing first or second eye cataract surgery only, no combined 
procedures. 
4. Must be over 18 years of age and have capacity to give consent. 
5. Must not have a drug allergy that precludes participation in the 
preoperative iodine prep, either study group, or topical eye drop regimen. 
6. Must not have an open infection of any kind or an infection near the eye. 
There are no eligibility requirements related to gender, race, socioeconomic 
status or sexual orientation and all eligible patients will be approached for 
participation in this study. Study subjects will be adult patients who are undergoing 
elective first or second eye clear corneal incision cataract surgery with intraocular lens 
implantation. Participants will be selected by contacting ophthalmology clinics 
associated with the New York-Presbyterian hospital system. Patients will be 
randomized into a study group and receive the assigned intracameral antibiotic—either 
1 mg cefuroxime or 250 mcg moxifloxacin— at the end of their cataract surgery. The 
groups will be matched for age, gender, race and socioeconomic status. 
Patients will be followed up at postoperative days 1 and 7 since postoperative 
endophthalmitis typically presents acutely, and at 28 days as well as 3 months 
postoperatively since postoperative endophthalmitis may sometimes be seen as late as 
several weeks following surgery.15 At each visit clinicians will assess operative eye 
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appearance, visual acuity, and perform a slit lamp exam to evaluate for postoperative 
endophthalmitis. Signs and symptoms of postoperative endophthalmitis include 
decreased visual acuity beyond what is expected for postoperative recovery, corneal 
edema, eyelid edema, conjunctival hyperemia, anterior chamber cells and flare, loss of 
red reflex, hypopyon and deep eye pain. In the event that a clinician determines a 
patient may have signs or symptoms of postoperative endophthalmitis, aqueous and 
vitreous samples will be collected for culture and sensitivity to differentiate between 
toxic anterior segment syndrome (TASS) and true endophthalmitis. 
2.5.3 Statistical Analysis 
Data will be analyzed using an independent samples two-tailed t test. A 95% 
confidence interval and a statistical significance of p<.05 will be used. The statistical 
power will be 0.8, or 80%. 
A priori power analysis was calculated based on reported rates of 
endophthalmitis of 0.06-0.25%14 which sets the mean for group 1 at 0.006 and the 
mean for group 2 at 0.025. The resultant effect size d of 0.038 with an α error 
probability of 0.05 and power of 0.8 determined a minimum total sample size of 
21,744 and group sample size of 10,872. 
2.5.4 Limitations 
There are several limitations to this study. First is the enrollment of a sufficient 
number of participants. A priori power analysis requires 21,744 participants, 10,872 in 
each group. The number of participants that are needed for enrollment is large, but in 
the context of how commonly performed cataract surgery is and how low the reported 
rates of endophthalmitis are, it is not unfounded. The requirement of thousands of 
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study participants is comparable to prior studies on the reduced incidence of 
postoperative endophthalmitis with use of intracameral antibiotics. The Shorstein et al 
study11 included over 16,000 participants and the ESCRS trial anticipated 35,000 
participants, and ultimately reached approximately 17,000 due to termination for 
ethical reasons regarding withholding treatment from the control group.  
Anticipated confounding variables include preoperative prep protocol, topical 
antibiotic regimen, patient compliance with the topical antibiotic regimen, occurrence 
of TASS, and loss of participants due to removal from study for occurrence of TASS 
or loss to follow-up. To eliminate and control confounding factors, all participating 
surgery centers and hospitals will have to meet minimum preoperative prep 
requirements (eye wash with iodine), the topical eye drop regimen will be unified for 
the study, results will be calculated with and without topical eye drop regimen 
compliance based on patient reporting, the occurrence of TASS will be differentiated 
from postoperative endophthalmitis by culture, cases of TASS will be removed from 
the study, and loss of participants will be compensated for by ongoing enrollment to 
meet at least 21,744 participants. 
2.5.5 Timeline 
IRB approval will be obtained by August 2016. Recruitment will begin in 
August 2016 with ongoing enrollment into the study. Enrollment will end in August 
2018, or when the study has reached at least 21,744 participants. Data collection will 
be conducted continuously as participants are seen at their follow-up appointments on 
postoperative days 1, 7, and 28 as well as 3 months postoperatively. The last 
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postoperative follow-up appointments will be in November 2018. Data analysis and 
dissemination of findings will be completed by November 2019. 
2.5.6 Conclusion 
 This will be the first two-arm, multi-center, randomized controlled study to 
directly compare and evaluate the rates of postoperative endophthalmitis in cataract 
surgery patients who received either prophylactic intracameral cefuroxime or 
prophylactic intracameral moxifloxacin. Intracameral administration of cefuroxime 
has become the unofficial standard of intracameral antibiotic prophylaxis in cataract 
surgery patients, although recent studies also show a decrease in rates of postoperative 
endophthalmitis in cataract surgery patients with the use of intracameral moxifloxacin. 
Data obtained from this study may help determine guidelines for best use practice 
regarding intracameral antibiotic prophylaxis, and subsequently prevent permanent 




In summary, this study hopes to help define the guidelines regarding the 
prophylactic administration of intracameral antibiotics in cataract surgery patients. 
The goal is to determine the best means of prophylaxis in order to preserve the sight 
and quality of life in as many cataract surgery patients as possible. Results obtained 
would provide ophthalmologists with evidence for the most appropriate intracameral 
antibiotic protocol for their patients. 
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